Semi-Quantitative and Quantitative $\text{[}^{18}\text{F}]$FDG-PET/CT Indices for Diagnosing Large Vessel Vasculitis: A Critical Review

Olivier Gheysens 1,*, François Jamar 1, Andor W. J. M. Glaudemans 2, Halil Yildiz 3 and Kornelis S. M. van der Geest 4

Abstract: To confirm the diagnosis of large vessel vasculitis (LVV) with high accuracy, one of the recommended imaging techniques is $\text{[}^{18}\text{F}]$FDG-PET/CT. Visual assessment of $\text{[}^{18}\text{F}]$FDG uptake parameters for diagnosing LVV and to provide future directions for methodological standardization and research.

Keywords: $\text{[}^{18}\text{F}]$FDG-PET/CT; giant cell arteritis; Takayasu’s arteritis; SUV

1. Introduction
1.1. The Clinical Spectrum

Large vessel vasculitis (LVV) is a generic term that encompasses a heterogeneous group of disorders characterized by inflammation of blood vessels of large and medium-sized caliber. The main forms are giant cell arteritis (GCA, sometimes referred to as temporal arteritis or Horton’s disease) and Takayasu’s arteritis (TAK). Isolated, noninfectious aortitis can be added to the spectrum but has a different clinical picture [1].

GCA and TAK are systemic vasculitides characterized by mononuclear and granulomatous infiltration of the vessel wall [2,3]. The clinical picture, though, is quite different: GCA is more frequent among Caucasians and occurs mainly over the age of 50. It can affect the large systemic arteries (i.e., large vessel GCA; lvGCA) and medium-sized cranial arteries (i.e., cranial GCA; cGCA). In view of this, the associated morbidity can be highly significant, extending from permanent blindness and stroke in cGCA to aortic aneurysm dissection in lvGCA [4]. TAK is found mainly in female patients younger than 40 years, with a predilection for Asian origin. TAK seems to differ from GCA by the extent and localization of vessel involvement, which involves more widely the mesenteric, renal and iliofemoral arteries, whilst mostly preserving the medium-sized cranial arteries [5].

The diagnosis of these disorders is principally established by the combination of clinical symptoms and laboratory parameters [5,6]. This includes (i) nonspecific constitutional symptoms such as malaise, fatigue, fever, weight loss, (ii) localized symptoms such as headache, and jaw claudication in GCA, and limb claudication and loss of pulse...
in TAK, and (iii) laboratory parameters of nonspecific inflammation, including a raised C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), as well as inflammation-related anemia and thrombocytopenia [7]. In addition, GCA may also occur together with polymyalgia rheumatica (PMR), with both diseases being described as a continuum, mostly in elderly patients [8].

The clinical symptoms and laboratory markers in GCA, TAK and isolated noninfectious aortitis are quite similar. The key issue is to make the correct diagnosis and to prevent damage by early and adequate treatment of vascular inflammation. High-dose glucocorticoids have remained the cornerstone of treatment in GCA and TAK. In addition, early addition of immunosuppressive treatments is advised in TAK, whilst this is also done increasingly in GCA [9].

1.2. The Role of Molecular Imaging

More than twenty years after the first description of a positive $^{18}$F Fluoro-2-deoxy-D-glucose positron emission tomography ($^{18}$F FDG-PET) in patients with aortitis [10], the technique has been widely used for establishing the diagnosis of large vessel vasculitis (LVV), as well as for assessing treatment efficacy in the regular clinical setting and in clinical trials. According to the EULAR 2018 recommendations, $^{18}$F FDG-PET/CT may be used as a first-line imaging technique to establish the diagnosis of lvGCA [11]. It also has the advantage of revealing inflammation in peri-articular and extra-articular structures in the case of polymyalgia rheumatica (PMR) and can help to exclude underlying malignant diseases or infections that may mimic the clinical symptoms of LVV. The uptake of $^{18}$F FDG depends on the expression of glucose transporters on various cell types, including acute and chronic inflammatory cells, endothelial cells or fibroblasts [12–14], but also on many tumor cells. As such, $^{18}$F FDG uptake cannot be deemed specific of systemic vascular inflammation but can also reflect tumoral infiltration, atheroma-related inflammation and inflammation associated with vascular infections. However, patterns of metabolic uptake may hint towards one or the other condition. Furthermore, the accuracy of $^{18}$F FDG-PET/CT in vasculitis is rapidly reduced after the initiation of glucocorticoid treatment [15,16].

Many studies proposed a variety of methods for interpreting $^{18}$F FDG-PET exams in this clinical indication. All those methods are based on the intensity of the glucose analog uptake going from intuitive visual assessment to structured visual scoring and finally semi-quantitative evaluation. Visual indices such as the 4-point scale (ranging from 0 to 3) [10] and visual grading score (vessel uptake compared to liver background) [17] have been proposed, and the latter is currently recommended by the European Society of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) [18]. In addition, a visual-based composite score, known as total vascular score (TVS), evaluating uptake in 7 to 11 different vascular regions, has been developed for diagnosing LVV [18,19]. Although vasculitides and scoring methods for interpretation were first explored using $^{18}$F FDG-PET, $^{18}$F FDG-PET/CT has now become the standard in modern imaging, allowing for the development of semi-quantitative or quantitative approaches, such as aorta to liver SUVmax ratio, vascular/liver ratio, vascular/lung ratio and arterial/venous ratio [20–22]. Nevertheless, there is a lack of a standardized definition. The objective of this review is to critically update the knowledge on semi-quantitative or quantitative methods of $^{18}$F FDG-PET/CT evaluation in the diagnosis and differentiation of LVV.

2. Methodology

2.1. Search Strategy

A comprehensive literature search of records through PubMed/MEDLINE databases was carried out until 5 August 2021. The following search algorithm combining several mesh terms was created and used: "large vessel vasculit* or giant cell arteritis or temporal arteritis or Horton or Takayasu arteritis or Takayasu AND fluorodeoxyglucose F18 or
fluorodeoxyglucose or FDG or positron-emission tomography or positron emission to-
mography computed tomography or positron emission tomograph * or positron-emission tomograph * or PET AND sensitivity or specificity or sensitive * or specificit * or accura * or SUV or semiquant * or semi-quant * or TBR”. The search was restricted to English-language
articles. No other restrictions were applied to the database search.

2.2. Study Selection

Titles and abstracts of the records were independently screened by two reviewers
(O.G., K.S.M.G.) based on predefined inclusion and exclusion criteria. Inclusion criteria
were original articles reporting information on the diagnostic accuracy (i.e., both sensitivity
and specificity) of semi-quantitative PET-derived parameters for a diagnosis of GCA or
TAK. Exclusion criteria were: (a) reviews, editorials, comments, letters or study protocols
related to the review question; (b) case reports or case series (less than 10 patients included)
related to the review question; (c) articles outside the field of interest of this review; and
(d) articles not available in English. The full text of the selected articles was independently
evaluated for its inclusion, and those who did not provide sufficient data with regard to
the review scope were excluded from this review.

2.3. Data Extraction

Two reviewers (O.G., K.S.M.G.) collected and cross-checked information about studies
and patient characteristics, including authors, year of publication, country, study design,
patient population, number of patients, ongoing glucocorticoid treatment, presence of
control group, the reference standard for LVV diagnosis, (semi-)quantitative index used
and diagnostic performance parameters. Technical details on $^{18}$F-FDG-PET/CT imaging
were not collected, but all included studies reported PET metrics corrected for attenuation.

3. Results

3.1. Literature Search

The comprehensive electronic database search of PubMed/MEDLINE identified
225 records, with the oldest reference dating from 2001. Overall, 213 records were excluded
after title/abstract screening and full-text evaluation since those provided no information
on the review question.

Twelve articles were eligible for a detailed description of the performance of (semi-)
quantiative PET-derived metrics for diagnosing GCA (cGCA and/or lvGCA) and/or TAK.

3.2. Study and Patient Characteristics

Table 1 summarizes the patient characteristics and main results of the included stud-
ies [15,22–32]. All selected articles were published in the past decade. All studies except
one were performed in Europe, and 75% (9/12) studies were retrospective in nature. All
studies included GCA patients, while only two studies explicitly mentioned the inclusion
of patients with TAK. More than half of the studies (7/12) also included at least some pa-
tients who received immunosuppressive treatment (mainly glucocorticoids) at the time of
$^{18}$F-FDG-PET/CT. Different reference standards were used among the studies to establish
the diagnosis of LVV, with 8/12 studies including temporal artery biopsy for a proportion
of all patients. The ACR 1990 criteria [7] were used in five studies, while the diagnosis for
at least some patients was made on clinical endpoints in three studies. One study did not
specify the diagnostic criterion or reference standard.
Table 1. Overview of studies reporting diagnostic accuracy of semi-quantitative indices for GCA or TAK. Only studies in which all patients underwent $^{18}$F-FDG-PET/CT were selected. † At least part of patients receiving treatment at the time of the scan. †† At least part of the patients received treatment for less than 3 days before the scan. FUO = fever of unknown origin. GCA = giant cell arteritis. ICV = inferior caval vein. IJV = internal jugular vein. SCV = superior caval vein. TAB = temporal artery biopsy. TAK = Takayasu’s arteritis. TVS = total vascular score.

| Authors and Year    | Country       | Study Design       | Patient Population | No. of Patients | Control Group Yes/No | No. of Controls | Reference Standard LVV                                      | (Semi-) Quantitative Index                      | Sensitivity | Specificity |
|---------------------|---------------|--------------------|--------------------|-----------------|----------------------|----------------|------------------------------------------------------------|------------------------------------------------|-------------|-------------|
| Rottenburger et al., 2021 | Switzerland | Retrospective      | Suspected GCA †    | 17 (GCA)        | Yes (suspected GCA but final diagnosis not GCA) | 17             | GiACTA trial criteria                                      | Visual FDG uptake at temporal artery (visible) | 53%         | 100%        |
|                     |               |                    |                    |                 |                      |                | TBR: SUVmax temporal artery/SUVmean liver > 1              |                                               | 53%         | 100%        |
| Nienhuis et al., 2020 | Netherlands  | Retrospective      | cGCA ††            | 24              | Yes (oncology)       | 24             | TAB positive                                               | Visual > background                       | 83%         | 75%         |
|                     |               |                    |                    |                 |                      |                | Visual ≥ liver                                             |                                               | 58%         | 96%         |
|                     |               |                    |                    |                 |                      |                | SUVmax > 5.0                                              |                                               | 79%         | 92%         |
| Imfeld et al., 2019 | Switzerland  | Retrospective      | Suspected GCA †    | 68 (GCA)        | Yes (suspected GCA but final diagnosis not -GCA) | 34             | TAB or ACR 1990 or incomplete ACR 1990 with positive imaging findings | TBR: SUVmax supra-aortic arteries/SUVmean liver > 1 and/or TBR: SUVmax aorta or iliofemoral arteries/SUVmean liver > 1.3 | 72%         | 85%         |
| Vaidyanathan et al., 2018 | United Kingdom | Retrospective      | Suspected LVV      | 17 (LVV)        | Yes (suspected LVV but final diagnosis not LVV) | 19             | Clinical diagnosis                                        | TVS (range 0–21) > 3.5                       | 79%         | 94%         |
|                     |               |                    |                    |                 |                      |                | TBR: SUVmax aorta/SUVmax liver > 1.0                      |                                               | 76%         | 100%        |
| Imfeld et al., 2017 | Switzerland  | Retrospective      | Suspected GCA †    | 68 (GCA)        | Yes (suspected GCA but final diagnosis not -GCA) | 35             | TAB or ACR 1990 or incomplete ACR 1990 with positive imaging findings | TBR: SUVmax supra-aortic arteries/SUVmean liver > 1.0 | 71%         | 91%         |
|                     |               |                    |                    |                 |                      |                | TBR: SUVmax thoracic aorta/SUVmean liver > 1.3            |                                               | 25%         | 91%         |
|                     |               |                    |                    |                 |                      |                | TBR: SUVmax abdominal aorta/SUVmean liver > 1.3            |                                               | 34%         | 91%         |
|                     |               |                    |                    |                 |                      |                | TBR: SUVmax iliofemoral arteries/SUVmean liver > 1.14     |                                               | 26%         | 91%         |
| Clifford et al., 2017 | Canada        | Prospective        | New-onset GCA †    | 28              | Yes (oncology)       | 28             | ACR 1990 and clinical diagnosis                            | Visual TVS (range 0–24) > 9                 | 71%         | 64%         |
| Castellani et al., 2016 | Italy         | Retrospective      | New-onset GCA/TAK  | 25              | Yes (oncology)       | 15             | Unclear                                                   | Visual TVS (range 0–33) > 8                  | 84%         | 87%         |
|                     |               |                    |                    |                 |                      |                | Average SUVmean > 0.697                                    |                                               | 96%         | 87%         |
| Stellingwerff et al., 2015 | Netherlands  | Retrospective      | New-onset GCA     | 12              | Yes (inflammation, atherosclerosis, normal)   | 53             | ACR 1990 or TAB or clinical diagnosis                      | Visual                                        | 92%         | 91% *        |
|                     |               |                    |                    |                 |                      |                | TBR: SUVmax aorta/SUVmax liver > 1.0                      |                                               | 83%         | 62%         |
|                     |               |                    |                    |                 |                      |                | TBR: SUVmax aorta/liver > 1.03                            |                                               | 92%         | 92%         |
|                     |               |                    |                    |                 |                      |                | TBR: SUVmax aorta/SCV > 1.4                               |                                               | 92%         | 73%         |
|                     |               |                    |                    |                 |                      |                | TBR: SUVmax aorta/ICV > 1.72                              |                                               | 75%         | 96%         |
| Authors and Year | Country | Study Design | Patient Population | No. of Patients | Control Group | No. of Controls | Reference Standard LVV | (Semi-) Quantitative Index | Sensitivity | Specificity |
|------------------|---------|--------------|-------------------|----------------|---------------|----------------|------------------------|-----------------------------|-------------|------------|
| Martinez-Rodriguez et al., 2014 | Spain | Prospective | Suspected LVV | 25 (LVV) | Yes (oncology) | 15 | Clinical and biochemical data, treatment response; TAB (n = 6) and MRA (n = 2) | SUVmax aorta wall > 1.74 | 80% | 83% |
| | | | | | | | | TBR: SUVmax aorta wall/lumen > 1.34 | 100% | 94% |
| | | | | | | | Mean SUVmax > 1.89 | 80% | 79% |
| | | | | | | | Mean SUVmax supra-aortic > 1.70 | 81% | 79% |
| | | | | | | | MeanSUVmax aorta > 2.25 | 90% | 42% |
| | | | | | | | MeanSUVmax aorta > 2.65 | 58% | 90% |
| Prieto-Gonzalez et al., 2014 | Spain | Prospective | New-onset GCA † | 32 | Yes (oncology) | 20 | TAB | Mean SUVmax > 1.89 | 80% | 79% |
| | | | | | | | Mean SUVmax supra-aortic > 1.70 | 81% | 79% |
| | | | | | | | MeanSUVmax aorta > 2.25 | 90% | 42% |
| | | | | | | | MeanSUVmax aorta > 2.65 | 58% | 90% |
| Besson et al., 2014 | France | Retrospective | GCA † | 11 | Yes (infection, oncology) | 11 | TAB | TBR: highest SUVmax aortic arch/highest SUVmax liver > 0.71 | 82% | 55% |
| | | | | | | | TBR: average SUVmax aortic arch/average SUVmax liver > 0.83 | 64% | 82% |
| | | | | | | | TBR: highest SUVmax aortic arch/SUVmax lung > 7.46 | 82% | 73% |
| | | | | | | | TBR: average SUVmax aortic arch/SUVmax lung > 6.9 | 73% | 73% |
| | | | | | | | TBR: highest SUVmax aortic arch/highest venous blood (Right IJV) > 1.53 | 82% | 91% |
| | | | | | | | TBR: average SUVmax aortic arch/average venous blood (Right IJV) > 1.63 | 82% | 73% |
| Lehmann et al., 2011 | Germany | Retrospective | GCA or TAK | 20 (GCA, n=17; TAK, n = 3) | Yes (oncology) | 20 | ACR 1990 or histology | Overall visual interpretation | 65% (data for 13 patients and 16 controls only) | 80% |
| | | | | | | | SUVmax > 1.78 | 90% | 45% |

*: average of the three subgroups of controls (specificity: 94%, 79%, 100% in arterial inflammation, atherosclerosis and normals, respectively).
3.3. Overview of (Semi-)Quantitative Parameters

The different (semi-)quantitative indices used across the included studies are listed in Table 1. Most of the studies (7/12) reported a target to background ratio (TBR). The reference organ for the TBR was the SUVmean or SUVmax of the liver (n = 6 studies), SUVmean or SUVmax of the vascular blood pool (n = 3 studies) and/or SUVmax of the lung (n = 1 study). A direct comparison of different reference organs was performed in two studies only. One study with non-treated GCA patients suggested that the liver as a reference organ provides better diagnostic accuracy than the blood pool [29]. Another study, in which some of the patients were already receiving treatment, suggested that the vascular blood pool might be better than the liver [22]. The diagnostic accuracy of the arterial SUVmean or SUVmax by itself, i.e., in the absence of a reference organ, was evaluated in 6/12 studies. Four studies used the SUVmax of the aorta wall with cut-off values ranging from 1.70 to 2.75 with large ranges in sensitivity and specificity, and with lower cut-off values usually yielding an increased sensitivity but decreased specificity. One study applied the SUVmax of the most active cranial artery with a cut-off > 5.0, resulting in a sensitivity of 79% and specificity of 92% for diagnosing cGCA [24]. Two studies indicated that a TBR provides higher diagnostic accuracy than a plain arterial SUVmean or SUVmax [29,30]. Three studies reported a total vascular score (TVS) which is a composite score of visual assessment of predefined vascular territories ranging from 7 to 11 vascular segments [15,26,28]. Optimal cut-off values differed significantly across these studies, with reported sensitivities and specificities ranging from 71% to 84% and 64% to 94%, respectively.

Only six studies, comprising 115 patients in total, performed a head-to-head comparison between visual interpretation (including TVS) and semi-quantitative indices [23,24,26,28,29,32]. In these studies, 148 subjects were considered as controls, mostly random oncology patients. No difference was found between the diagnostic performance of visual and semi-quantitative assessment (when using only the best performing semi-quantitative index per study, to avoid biases from unequal datasets) when using Youden indices (i.e., [sensitivity + specificity] − 1) for these six studies. The mean (s.d.) Youden index was 0.64 (0.14) vs. 0.67 (0.19) for the visual index and various semi-quantitative indices, respectively. Stellingwerff et al. confirmed by separately analyzing patients with or without glucocorticoid treatment that the diagnostic accuracy of visual interpretation and the TBR semi-quantitative indices was lower in patients on glucocorticoids, whilst no significant difference was observed for the SUVmax aorta [29].

4. Discussion

From this review, there is little information that guides the diagnosis of large vessel vasculitis towards semi-quantitative indices. Six studies allowed comparing the diagnostic performance of semi-quantitative versus visual indices in the same patient population. Since the diagnostic performance of a visual or metrical approach is always a balance between sensitivity and specificity, we evaluated the Youden index in these studies, which did not show any difference between both methods.

There may, however, be particular situations in which, on due knowledge, the interpretation of \[^{18}\text{F}]FDG-PET/CT may be mitigated. This is especially the case in elderly patients in whom uptake in atherosclerotic plaques may be observed, leading to a reduced specificity in identifying LVV. Even though an overlap exists and differentiating active vasculitis from atherosclerosis can be challenging, several PET uptake characteristics may hint towards one condition. Vasculitis typically appears as a linear, diffuse and circumferential uptake, while atherosclerosis rather presents as a patchy uptake with lower intensity. This does not hold true in younger patients with a suspicion of TAK but remains a diagnostic challenge in older and especially elderly patients in whom GCA can be suspected, as has been shown by Besson et al. [22].

From the data collected herein, there is no evidence that semi-quantitative \[^{18}\text{F}]FDG-PET/CT metrics may help to better diagnose LVV than visual scoring. Visual analysis or a
qualitative metric based on visual analysis such as the TVS should remain the privileged way to make due interpretation of the so-called routine $^{18}$F-FDG-PET/CT. A similar conclusion was already made by Puppo et al. in 2014 [33] in a review on $^{18}$F-FDG-PET in vasculitis where stand-alone PET studies were included, whereas the current review focuses on hybrid PET/CT studies. In addition, the visual analysis showed very good interobserver reproducibility, which is essential for daily clinical practice, where the actual report is used for clinical decision-making [34]. Moreover, quantitative strategies usually require a certain experience and rigorous application of the methodology, e.g., drawing regions or volumes of interest on the arterial segments, which is time-consuming, operator dependent and not feasible in routine clinical practice. Another compelling reason to refrain from quantitative metrics such as SUV-based methods in clinical routine is related to the inappropriate application of literature-derived cut-off values for sensitivity and specificity in establishing the diagnosis of LVV. Indeed, a quantitative metric can only be correctly used/extrapolated to its own clinical practice if imaging characteristics affecting the metric such as voxel size, filtering, etc., are harmonized and standardized across different PET cameras. Arterial wall thicknesses are most generally in the range of 2–5 mm, and this raises a major issue of partial volume effect. This has not been addressed in LVV but was shown as a significant hurdle for assessing semi-quantitative data on vascular $^{18}$F-FDG uptake in the field of atherosclerosis [35]. Such impact in assessing large and medium-sized vessel activity in LVV is most likely similar, i.e., thresholds for pathological results are often exceeded in normal volunteers. Even though efforts have been made by publishing joint procedural recommendations, e.g., adherence to EANM Research GmbH (EARL) [18], achieving the highest level of standardization remains utopic at this time.

This patient population is at risk of sometimes severe and dramatic complications such as stroke or blindness. Therefore it is not uncommon that glucocorticoid therapy has been initiated before $^{18}$F-FDG-PET/CT will be performed. Nielsen et al. demonstrated that a few days on oral glucocorticoids did not change the diagnostic performance of the test, but that further on, the sensitivity decreased for visual interpretation [16]. In a sub-analysis of one report [29], the authors demonstrated that the diagnostic accuracy of TBR-based semi-quantitative indices was also reduced in patients under glucocorticoids, underscoring that $^{18}$F-FDG-PET/CT exams in patients on glucocorticoid treatment should be interpreted with caution. Only the SUVmax aorta showed better accuracy in patients with glucocorticoid treatment than in those without.

Nevertheless, semi-quantitative or quantitative indices may have an added and complementary role in clinical research trials. In these trials, consistency and congruency of imaging characteristics are of utmost importance since patients are often imaged at different time points or during treatment. Indeed, a recent systematic review suggested that TBR-based semi-quantitative indices might potentially be more responsive to change than composite scores based on visual assessment [36]. The best parameter to be applied in clinical studies is yet to be determined, and well-designed clinical trials may provide an answer to the value and indication of quantitative PET in LVV.

5. Conclusions

There is currently no evidence that semi-quantitative indices surpass visual analysis of $^{18}$F-FDG-PET/CT for diagnosing LVV. Visual analysis should remain the standard of care by looking at vascular distribution, depending on the suspected disease and the intensity of uptake as compared with general vascular or, as a surrogate, liver activity. Semi-quantitative indices, based on ratios, shall be implemented in clinical trials only with a well-defined calculation. In the future, large multicentric studies should focus on determining ONE single parameter that can be used in all studies and could further be implemented in clinical practice. The no-go of beyond three days glucocorticoid treatment should be enforced in all such studies before data can be used truthfully in daily clinical practice.
Author Contributions: O.G. and K.S.M.v.d.G. performed the literature search and data extraction. All authors (O.G., K.S.M.v.d.G., F.J., A.W.J.M.G., H.Y.) contributed to the drafting and revision of the manuscript and validated the submitted version. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Jennette, J.C.; Falk, R.J.; Bacon, P.A.; Basu, N.; Cid, M.C.; Ferrario, F.; Flores-Suarez, L.F.; Gross, W.L.; Guillevin, L.; Hagen, E.C.; et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum.* 2013, 65, 1–11. [CrossRef] [PubMed]
2. Van der Geest, K.S.M.; Sandovici, M.; van Sleek, Y.; Sandres, J.-S.; Bos, N.A.; Abdulahad, W.H.; Steegman, C.A.; Heeringa, P.; Rutgers, A.; Kallenberg, C.G.M.; et al. Review: What is the current evidence for disease subsets in giant cell arteritis? *Arthritis Rheumatol.* 2018, 70, 1366–1376. [CrossRef]
3. Serra, R.; Buttrico, L.; Fugetto, F.; Chibireva, M.D.; Malva, A.; De Caridi, G.; Massara, M.; Barbetta, A.; Cannistrà, M.; De Franciscis, S. Updates in Pathophysiology, Diagnosis and Management of Takayasu Arteritis. *Ann. Vasc. Surg.* 2016, 35, 210–225. [CrossRef] [PubMed]
4. Soriano, A.; Muratore, F.; Pipitone, N.; Boiardi, L.; Cimino, L.; Salvarani, C. Visual loss and other cranial ischaemic complications in giant cell arteritis. *Nat. Rev. Rheumatol.* 2017, 13, 476–484. [CrossRef]
5. Koster, M.J.; Warrington, K.J. Classification of large vessel vasculitis: Can we separate giant cell arteritis from Takayasu arteritis? *La Presse Médicale* 2017, 46, e205–e213. [CrossRef] [PubMed]
6. van der Geest, K.S.M.; Sandovici, M.; Brouwer, E.; Mackie, S.L. Diagnostic accuracy of symptoms, physical signs, and laboratory tests for giant cell arteritis: A systematic review and meta-analysis. *JAMA Intern. Med.* 2020, 180, 1295–1304. [CrossRef] [PubMed]
7. Hunder, G.G.; Bloch, D.A.; Michel, B.A.; Stevens, M.B.; Arend, W.P.; Clabrese, L.H.; Edworthy, S.M.; Fauci, A.S.; Leavitt, R.Y.; Lie, J.T.; et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis: Introduction. *Arthritis Rheum.* 1990, 33, 1122–1129. [CrossRef]
8. Kermani, T.A.; Warrington, K.J. Polymyalgia rheumatica. *Lancet* 2013, 381, 63–72. [CrossRef]
9. Hellmich, B.; Agueda, A.; Monti, S.; Buttgereit, F.; De Boysson, H.; Brouwer, E.; Cassie, R.; Cid, M.C.; Dasgupta, B.; Dejaco, C.; et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. *Ann. Rheum. Dis.* 2020, 79, 19–30. [CrossRef] [PubMed]
10. Blockmans, D.; Maes, A.; Stroobants, S.; Nuys, J.; Bormans, G.; Knockaert, D.; Bobbaers, H.; Mortelmans, L. New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography. *Rheumatology* 1999, 38, 444–447. [CrossRef] [PubMed]
11. Dejaco, C.; Ramiro, S.; Dufnner, C.; Besson, F.L.; Bley, T.A.; Blockmans, D.; Brouwer, E.; Cimmino, M.A.; Clark, E.; Dasgupta, B.; et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. *Ann. Rheum. Dis.* 2018, 77, 636–643. [CrossRef]
12. Kubota, R.; Yamada, S.; Kubota, K.; Ishiwashi, K.; Tamahashi, N.; Ido, T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studies by microautoradiography. *J. Nucl. Med.* 1992, 33, 1972–1980.
13. Fu, Y.; Maianu, L.; Melbert, B.R.; Garvey, W.T. Facilitative glucose transporter gene expression in human lymphocytes, monocytes, and macrophages: A role for GLUT isoforms 1, 3, and 5 in the immune response and foam cell formation. *Blood Cells Mol. Dis.* 2004, 32, 182–190. [CrossRef]
14. Matsui, T.; Nakata, N.; Nagai, S.; Nakatani, A.; Takahashi, M.; Momose, T.; Ohtomo, K.; Koyasu, S. Inflammatory Cytokines and Hypoxia Contribute to 18F-FDG Uptake by Cells Involved in Pannus Formation in Rheumatoid Arthritis. *J. Nucl. Med.* 2009, 50, 920–926. [CrossRef]
15. Clifford, A.H.; Murphy, E.M.; Burrell, S.C.; Bligh, M.P.; MacDougall, R.F.; Heathcote, J.G.; Castonguay, M.C.; Lee, M.S.; Matheson, K.; Hanly, J.G. Positron Emission Tomography/Computerized Tomography in Newly Diagnosed Patients with Giant Cell Arteritis Who Are Taking Glucocorticoids. *J. Rheumatol.* 2017, 44, 1859–1866. [CrossRef]
16. Nielsen, B.D.; Gormsen, L.C.; Hansen, I.T.; Keller, K.K.; Therkildsen, P.; Hauge, E.M. Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy. *Eur. J. Nucl. Med. Mol. Imaging* 2018, 45, 1119–1128. [CrossRef]
17. Meller, J.; Strutz, F.; Siefker, U.; Scheel, A.; Sahlmann, C.O.; Lehmann, K.; Conrad, M.; Vossenrich, R. Early diagnosis and follow-up of aortitis with [18F]FDG PET and MRI. *Eur. J. Nucl. Med. Mol. Imaging* 2003, 30, 730–736. [CrossRef]
18. Slart, R.H.J.A. Writing Group; Reviewer Group; Members of EANM Cardiovascular; Members of EANM Infection & Inflammation; Members of Committees; SNMMI Cardiovascular; Members of Council; PET Interest Group; Members of ASNC & EANM Committee Coordinator. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: Joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 1250–1269. [CrossRef]

19. Malik, D.; Verma, R.; Gupta, V.; Belho, E.S.; Drolia, B.; Seniary, N.; Mahajan, H. Semiquantitative interpretation criteria for fluorodeoxyglucose-position emission tomography/computed tomography in large-vessel vasculitis: Pattern recognition and correlation with polymyalgia rheumatica. Indian J. Nucl. Med. 2020, 35, 6–12. [CrossRef]

20. Hautzel, H.; Sander, O.; Heinzl, A.; Schneider, M.; Müller, H.-W. Assessment of Large-Vessel Involvement in Giant Cell Arteritis with 18F-FDG PET: Introducing an ROC-Analysis-Based Cutoff Ratio. J. Nucl. Med. 2008, 49, 1107–1113. [CrossRef]

21. Moossig, F.; Czech, N.; Mehl, C.; Henze, E.; Zeuner, R.A.; Kneba, M.; Schröder, J.O. Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: A quantitative PET study. Ann. Rheum. Dis. 2004, 63, 870–873. [CrossRef]

22. Besson, F.L.; de Boysson, H.; Parienti, J.-J.; Bouvard, G.; Bienvenu, B.; Agostini, D. Towards an optimal semiquantitative approach in giant cell arteritis: An 18F-FDG PET/CT case-control study. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 155–166. [CrossRef]

23. Rottenburger, C.; Mensch, N.; Imfeld, S.; Aschwanden, M.; Glatz, K.; Staub, D.; Berger, C.; Daikeler, T. 18F-FDG PET/CT compared with ultrasound and biopsy for detection of vasculitis of the temporal artery branches. Swiss Med. Wkly. 2021, 151, w20512. [CrossRef]

24. Nienhuis, P.H.; Sandovici, M.; Glaudemans, A.W.J.M.; Slart, R.H.J.M.; Brouwer, E. Visual and semiquantitative assessment of cranial artery inflammation with FDG-PET/CT in giant cell arteritis. Semin. Arthritis Rheum. 2020, 50, 616–623. [CrossRef]

25. Imfeld, S.; Aschwanden, M.; Rottenburger, C.; Scheck, E.; Berger, C.T.; Staub, D.; Daikeler, T. [18F]FDG positron emission tomography and ultrasound in the diagnosis of giant cell arteritis: Congruent or complementary imaging methods? Rheumatology 2020, 59, 772–778. [CrossRef]

26. Vaidyanathan, S.; Chattopadhayay, A.; Mackie, S.L.; Scarsbrook, A.F. Comparative effectiveness of 18F-FDG PET-CT and contrast-enhanced CT in the diagnosis of suspected large-vessel vasculitis. Br. J. Radiol. 2018, 81, 20180247. [CrossRef]

27. Imfeld, S.; Rottenburger, C.; Scheck, E.; Aschwanden, M.; Juengling, F.; Staub, D.; Recher, M.; Kyburz, D.; Berger, C.T.; Daikeler, T. [18F]FDG positron emission tomography in patients presenting with suspicion of giant cell arteritis—lessons from a vasculitis clinic. Eur. Hear. J. Cardiovasc. Imaging 2018, 19, 933–940. [CrossRef]

28. Castellani, M.; Vadrucci, M.; Florimonte, L.; Caronni, M.; Beniti, R.; Bonara, P. 18F-FDG uptake in main arterial branches of patients with large vessel vasculitis: Visual and semiquantitative analysis. Ann. Nucl. Med. 2016, 30, 409–420. [CrossRef]

29. Stellingwerff, M.D.; Brouwer, E.; Lensen, K.-J.D.F.; Rutgers, A.; Arends, S.; van der Geest, K.S.M.; Glaudemans, A.W.J.M.; Slart, R.H.J.A. Different Scoring Methods of FDG PET/CT in Giant Cell Arteritis. Medicine 2015, 94, e1542. [CrossRef]

30. Martínez-Rodriguez, I.; Martínez-Amador, N.; Banzo, I.; Quirce, R.; Jiménez-Bonilla, J.; De Acococh-Torres, M.; Ibáñez-Bravo, S.; Lavado-Pérez, C.; Bravo-Ferrer, Z.; Blanco, R.; et al. Assessment of aortitis by semiquantitative analysis of 180-min 18F-FDG PET/CT acquisition images. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 2319–2324. [CrossRef]

31. Prieto-González, S.; Depetris, M.; García-Martínez, A.; Espigol-Frigolé, G.; Tavera-Bahillo, I.; Corbera-Bellata, M.; Planas-Rigol, E.; Alba, M.A.; Hernández-Rodriguez, J.; Grau, J.M.; et al. Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: A prospective, case–control study. Ann. Rheum. Dis. 2014, 73, 1388–1392. [CrossRef]

32. Lehmann, P.; Buchtala, S.; Achajew, N.; Haerle, P.; Ehrenstein, B.; Lighvani, H.; Fleck, M.; Marienhagen, J. 18F-FDG PET as a diagnostic procedure -in large vessel vasculitis-a controlled, blinded re-examination of routine PET scans. Clin. Rheumatol. 2011, 30, 37–42. [CrossRef]

33. Puppo, C.; Massolo, M.; Paparo, F.; Camellino, D.; Piccardo, A.; Naseri, M.S.Z.; Villaevacchia, G.; Rollandi, G.A.; Cimmino, M.A. Giant Cell Arteritis: A Systematic Review of the Qualitative and Semiquantitative Methods to Assess Vasculitis with 18F-Fluorodeoxyglucose Positron Emission Tomography. BioMed Res. Int. 2014, 2014, 57428. [CrossRef]

34. Lensen, K.D.F.; Comans, E.F.I.; Voskuyl, A.E.; Van Der Laken, C.J.; Brouwer, E.; Zwijnenburg, A.T.; Pereira Arias-Bouda, L.M.; Glaudemans, A.; Slart, R.H.J.A.; Smulders, Y.M.; et al. Large-Vessel Vasculitis: Interobserver Agreement and Diagnostic Accuracy of [18F]FDG-PET/CT. BioMed Res. Int. 2015, 2015, 914692. [CrossRef]

35. Van der Valk, F.M.; Verweij, S.L.; Zwinderman, K.A.; Strang, A.C.; Kaiser, Y.; Marquering, H.A.; Nederveen, A.J.; Stroes, E.S.; Verberne, H.J.; Rudd, J.H. Thresholds for arterial wall inflammation quantified by (18)F-FDG PET Imaging: Implications for vascular interventional studies. JACC Cardiovasc. Imaging 2016, 9, 1198–1207. [CrossRef]

36. Van der Geest, K.S.M.; Treglia, G.; Glaudemans, A.W.J.M.; Brouwer, E.; Sandovici, M.; Jamar, F.; Ghysens, O.; Slart, R.H.J.A. Diagnostic value of [18F]FDG-PET/CT for treatment monitoring in large vessel vasculitis: A systematic review and meta-analysis. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 3886–3902. [CrossRef]